Kiora Pharmaceuticals (NASDAQ:KPRX) Releases Quarterly Earnings Results, Misses Expectations By $0.40 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) announced its quarterly earnings data on Tuesday. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.40), Zacks reports. The business had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.75 million.

Kiora Pharmaceuticals Stock Performance

Shares of NASDAQ:KPRX opened at $2.99 on Thursday. The firm has a market cap of $8.97 million, a PE ratio of 2.88 and a beta of -0.46. The firm’s 50 day simple moving average is $3.49 and its 200-day simple moving average is $3.48. Kiora Pharmaceuticals has a one year low of $2.91 and a one year high of $6.48.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.